Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin J Solomon

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Clinical Lung Cancer|September 23, 2022
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic ConsiderationsMyung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.
The New England Journal of Medicine|September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancerAlice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
The Lancet. Oncology|September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.
BMJ Open|July 5, 2024
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET CollaborationKristy P Robledo, Shilo Lefresne, Yu Yang Soon, et al.
JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
JCO Precision Oncology|February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2026
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trialsChee Khoon Lee, Shilo Lefresne, Yu Yang Soon, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Future Oncology (London, England)|March 25, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summaryAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Journal of Cancer Policy|November 26, 2023
A tailored approach to horizon scanning for cancer medicinesJennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Clinical Lung Cancer|September 23, 2022
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic ConsiderationsMyung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.
The New England Journal of Medicine|September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancerAlice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
The Lancet. Oncology|September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.
BMJ Open|July 5, 2024
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET CollaborationKristy P Robledo, Shilo Lefresne, Yu Yang Soon, et al.
JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
JCO Precision Oncology|February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2026
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trialsChee Khoon Lee, Shilo Lefresne, Yu Yang Soon, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Future Oncology (London, England)|March 25, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summaryAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Journal of Cancer Policy|November 26, 2023
A tailored approach to horizon scanning for cancer medicinesJennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Pageof 13